FA new injection to prevent HIV is expected to be approved by the U.S. Food and Drug Administration (FDA) later this month.

This was the stock's second consecutive day of gains.

Gilead's HIV drug lenacapavir earns FDA priority review after strong trial results, with the company planning to double U.S.

A Gilead Sciences-backed therapy made with a patient's own white blood cells shrank tumors in 62% of patients with recurrent ...

Drugmakers unveil cancer drug data at the ASCO annual meeting, while Amazon Pharmacy announces new features for caregivers, ...

Jefferies analyst Michael Yee reaffirmed a Buy rating on Gilead Sciences Inc. (NASDAQ:GILD), maintaining his price target at ...

By Deena Beasley (Reuters) -Gilead Sciences' Trodelvy in combination with Merck's blockbuster immunotherapy Keytruda lowered ...

Gilead Sciences is well-positioned to continue to strengthen its position as a leader in the HIV therapy market. Learn more ...

Spoiler alert! Here's how Hulu's "The Handmaid's Tale" ends after six long seasons of June (Elisabeth Moss) in Gilead.

Gilead Sciences' TROP2-targeting drug Trodelvy is already used as a third-line treatment for PD-L1-positive triple-negative ...

(Reuters) -Gilead Sciences says it still plans to supply its twice-yearly injection for preventing HIV infection in ...